By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Edge Therapeutics 

NJIT-EDC Biotechnology Incubator
139 South Street, Suite 102
New Providence  New Jersey  07974  U.S.A.
Phone: 800-208-EDGE Fax: 800-208-3433



Company News
Edge Therapeutics Names W. Bradford Middlekauff As Senior Vice President, General Counsel And Secretary 11/5/2015 9:58:49 AM
Edge Therapeutics Announces Closing Of Initial Public Offering And Full Exercise Of Over-Allotment Option 10/7/2015 10:00:26 AM
Edge Therapeutics Reports Positive Top-Line Phase I/II NEWTON Trial Results Of EG-1962 In Aneurysmal Subarachnoid Hemorrhage 8/19/2015 8:12:46 AM
Edge Therapeutics Files for $115 Million 8/18/2015 7:49:13 AM
Edge Therapeutics’ Chief Executive Officer Brian Leuthner Receives EY Entrepreneur Of The Year 2015 New Jersey Region Award 6/29/2015 12:48:17 PM
Edge Therapeutics Receives FDA Orphan Drug Designation For EG-1962 For The Treatment Of Patients With Subarachnoid Hemorrhage 6/5/2015 9:27:09 AM
Edge Therapeutics Completes Enrollment In Phase 1/2 NEWTON Study Of EG-1962 For Patients With Ruptured Brain Aneurysm 5/28/2015 9:51:27 AM
Edge Therapeutics Banks $72.5 Million for Phase III Brain Hemorrhage Study 4/9/2015 5:15:44 AM
Edge Therapeutics Reports Initial Data From Its Phase 1/2 NEWTON Trial For EG-1962 For Improvement Of Outcomes After Ruptured Brain Aneurysm 2/11/2015 11:01:41 AM
Edge Therapeutics Announces Appointment Of Renu Vaish, M.S. As Vice President, Regulatory Affairs 1/8/2015 10:50:17 AM